21-DEC-2024 6:10

MMYEL ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1803-MM, Maintenance, Len vs Len/Dara 1 Y 0 Screening 1420 1406 261 136 79 22 5 08/13/2019 328 128
            1406 261 136 79 22 5      
 
    2 Y 1 Lenalidomide   647 117 62 35 10 3 08/13/2019    
        2 Lenalidomide + Daratumumab   639 121 61 34 12 2      
            1286 238 123 69 22 5      
 
    3 Y 3 Stop vs Continue Treatment   222 68 34 19 3 1 08/13/2019    
            222 68 34 19 3 1      
 
  S2005-WM, Prev. Untreated, I/R +/- Venetoclax 1 Y 1 I+R 92 5 5 4 3 1 0 01/05/2022 83 28
        2 I+R+Venetoclax   1 0 0 0 0 0      
        3 V+R   4 4 3 1 0 0      
            10 9 7 4 1 0      
 
  S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 1 Y 1 VRD-R 510 19 17 10 6 3 0 10/12/2023 220 81
        2 DRD-R   19 17 10 4 3 1      
        3 DRD-DR   17 15 8 4 0 0      
            55 49 28 14 6 1      
 
  S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 1 Y 0 Induction 338 5 5 5 2 0 0 07/01/2024 117 36
            5 5 5 2 0 0      
 
    2 Y 1 Dara-VCD   1 1 1 1 0 0 07/01/2024    
        2 Melphalan + ASCT   1 1 1 1 1 1      
            2 2 2 2 1 1      
 
Yes EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 0 E Total Registrations   50 7 4 1 0 0 05/27/2021 205 81
            50 7 4 1 0 0      
 
    1 E Total Registrations   37 7 2 1 0 0 05/27/2021    
            37 7 2 1 0 0      
 
    2 E Total Registrations   28 15 7 3 1 0 05/27/2021    
            28 15 7 3 1 0      
 
No EAA173-MYEL, SMM, Rd +/- Daratumumab 0 E Total Registrations   75 18 8 4 1 0 01/08/2020 245 102
            75 18 8 4 1 0      
 
    1 E Total Registrations   37 11 5 4 2 0 01/08/2020    
            37 11 5 4 2 0      
 

21-DEC-2024 6:10

MMYEL Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
S2005 WM, Prev. Untreated, I/R +/- Venetoclax 2 Crossover 24-Jun-21 83 28
S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 3 Maintenance 01-Dec-23 117 36